for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CytomX Therapeutics Inc

CTMX.OQ

Latest Trade

7.11USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.64

 - 

19.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

CytomX Therapeutics Announces Qtrly Loss Per Share $0.64

Aug 7 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 REVENUE $9.0 MILLION VERSUS $21.3 MILLION.Q2 REVENUE ESTIMATE $16.6 MILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, CYTOMX HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $349.1 MILLION.QTRLY LOSS PER SHARE $0.64.

CytomX Therapeutics Reports Second Target Selection And Program Initiation With AbbVie

July 9 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES SECOND TARGET SELECTION AND PROGRAM INITIATION WITH ABBVIE UNDER ONGOING, MULTI-PROGRAM STRATEGIC ONCOLOGY COLLABORATION.CYTOMX THERAPEUTICS INC - SECOND TARGET SELECTION BY ITS PARTNER ABBVIE UNDER COMPANIES' 2016 DISCOVERY COLLABORATION AND LICENSING AGREEMENT.CYTOMX THERAPEUTICS INC - TARGET SELECTION TRIGGERS A $10 MILLION PAYMENT TO CYTOMX FROM ABBVIE.CYTOMX THERAPEUTICS INC - ADVANCING A CLINICAL-STAGE ASSET, CX-2029, UNDER A GLOBAL CO-DEVELOPMENT AND LICENSING AGREEMENT.

CytomX Therapeutics Says On May 22, Board Designated Dr. Sean Mccarthy, Co's Chairman & CEO, To Assume Responsibilities Of Principal Financial Officer

May 29 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS - ON MAY 22, BOARD DESIGNATED DR. SEAN MCCARTHY, CO'S CHAIRMAN & CEO, TO ASSUME RESPONSIBILITIES OF PRINCIPAL FINANCIAL OFFICER.CYTOMX THERAPEUTICS - MCCARTHY'S APPOINTMENT FOLLOWS DEPARTURE OF DEBANJAN RAY, CO'S FORMER CFO WHOSE RESIGNATION BECAME EFFECTIVE ON MAY 15, 2019..CYTOMX THERAPEUTICS - BOARD DESIGNATED ROBIN KNIFSEND, TO ASSUME RESPONSIBILITIES OF PRINCIPAL ACCOUNTING OFFICER, EFFECTIVE IMMEDIATELY.

Cytomx Therapeutics Announces Transition Of Chief Financial Officer

March 25 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES TRANSITION OF CHIEF FINANCIAL OFFICER.CYTOMX THERAPEUTICS INC - DEBANJAN RAY, WILL BE STEPPING DOWN FROM COMPANY, EFFECTIVE MAY 15, 2019.CYTOMX THERAPEUTICS INC - RAY WILL CONTINUE TO BE AVAILABLE AS AN ADVISOR TO COMPANY AFTER HIS DEPARTURE.

Cytomx Therapeutics Announces Full-Year 2018 Financial Results

Feb 27 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2018 FINANCIAL RESULTS.

CytomX Therapeutics CEO Appointed To Additional Role Of Chairman

Dec 20 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS.CEO SEAN MCCARTHY APPOINTED TO ADDITIONAL ROLE OF CHAIRMAN.BOARD CHAIRMAN HOYOUNG HUH WILL RETIRE FROM BOARD EFFECTIVE DECEMBER 31, 2018.

Cytomx Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million

Nov 6 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION .

CytomX Therapeutics Qtrly Loss Per Share $0.53

Nov 6 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 REVENUE $12.5 MILLION VERSUS $24.1 MILLION.Q3 REVENUE VIEW $16 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.53.Q3 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.

Cytomx Therapeutics Inc - QTRLY Net Loss Per Share $0.35

CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $21.3 MILLION VERSUS I/B/E/S VIEW $19.2 MILLION.QTRLY NET LOSS PER SHARE $0.35.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.

Cytomx Therapeutics Says Public Offering Of 5.10 Mln Common Shares Priced At $24.50/ Share

July 12 (Reuters) - CytomX Therapeutics Inc <CTMX.O>::CYTOMX THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.10 MILLION COMMON SHARES PRICED AT $24.50PER SHARE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up